Pharmacokinetics of cefotaxime and desacetylcefotaxime in infants during extracorporeal membrane oxygenation

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 5, 2010, Pages 1734-1741

  Ahsman, Maurice J ^a   Wildschut, Enno D ^b   Tibboel, Dick ^b   Mathot, Ron A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOTAXIME; DEACETYLCEFOTAXIME;

ARTICLE; BACTERIAL MENINGITIS; BLOOD SAMPLING; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; EXTRACORPOREAL OXYGENATION; FEMALE; HUMAN; INFANT; MALE; MAXIMUM PLASMA CONCENTRATION; MEDICAL EXAMINATION; METABOLITE; MINIMUM INHIBITORY CONCENTRATION; NEWBORN; PERINATAL PERIOD; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CEFOTAXIME; CRITICAL ILLNESS; CROSS INFECTION; EXTRACORPOREAL MEMBRANE OXYGENATION; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MEDICAL RECORDS; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; RESPIRATION, ARTIFICIAL;

EID: 77951249586     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01696-09     Document Type: Article

References (33)

1. Ahsman, M. J., M. Hanekamp, E. D. Wildschut, D. Tibboel, and R. A. Mathot. Population pharmacokinetics of midazolam and metabolites during venoarterial extracorporeal membrane oxygenation in neonates. Clin. Pharmacokinet., in press.
2. Ahsman, M. J., E. D. Wildschut, D. Tibboel, and R. A. Mathot. 2009. Microanalysis of beta-lactam antibiotics and vancomycin in plasma for pharmacokinetic studies in neonates. Antimicrob. Agents Chemother. 53:75-80.
3. Amaker, R. D., J. T. DiPiro, and J. Bhatia. 1996. Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation. Antimicrob. Agents Chemother. 40:1139-1142.
4. Anderson, B. J., K. Allegaert, and N. H. Holford. 2006. Population clinical pharmacology of children: modelling covariate effects. Eur. J. Pediatr. 165: 819-829.
5. Bennett, C. C., and C. F. Davis. 2003. Evidence-based use of neonatal extracorporeal membrane oxygenation (ECMO). Curr. Paediatr. 2003:146-150.
6. Bertels, R. A., B. A. Semmekrot, G. P. Gerrits, and J. W. Mouton. 2008. Serum concentrations of cefotaxime and its metabolite desacetyl-cefotaxime in infants and children during continuous infusion. Infection 36:415-420.
7. Buck, M. L. 2003. Pharmacokinetic changes during extracorporeal membrane oxygenation: implications for drug therapy of neonates. Clin. Pharmacokinet. 42:403-417.
8. Cook, L. N. 2004. Update on extracorporeal membrane oxygenation. Paediatr. Respir. Rev. 5(Suppl. A):S329-S337.
9. de Hoog, M., J. W. Mouton, and J. N. van den Anker. 2005. New dosing strategies for antibacterial agents in the neonate. Semin. Fetal Neonatal Med. 10:185-194.
10. Ette, E. I. 1997. Stability and performance of a population pharmacokinetic model. J. Clin. Pharmacol. 37:486-495.
11. Fanos, V., and A. Dall'Agnola. 1999. Antibiotics in neonatal infections: a review. Drugs 58:405-427.
12. Harrison, A. M., S. Davis, S. Eggleston, R. Cunningham, R. B. Mee, and P. M. Bokesch. 2003. Serum creatinine and estimated creatinine clearance do not predict perioperatively measured creatinine clearance in neonates undergoing congenital heart surgery. Pediatr. Crit. Care Med. 4:55-59.
13. Hartwig, N. G., P. C. J. De Laat, and L. M. Hanff (ed.). 2005. Vademecum pediatrische antimicrobiële therapie (handbook of pediatric antimicrobial therapy), 3rd ed. Erasmus University Medical Center, Rotterdam, Netherlands.
14. Hooker, A. C., C. E. Staatz, and M. O. Karlsson. 2007. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm. Res. 24:2187-2197.
15. Hsu, M. S., K. M. Chiu, Y. T. Huang, K. L. Kao, S. H. Chu, and C. H. Liao. 2009. Risk factors for nosocomial infection during extracorporeal membrane oxygenation. J. Hosp. Infect. 73:210-216.
16. Jacobs, R. F. 1991. Efficacy and safety of cefotaxime in the management of pediatric infections. Infection 19(Suppl. 6):S330-S336.
17. Jones, R. N. 1995. Cefotaxime and desacetylcefotaxime antimicrobial interactions. The clinical relevance of enhanced activity: a review. Diagn. Microbiol. Infect. Dis. 22:19-33.
18. Jonsson, E. N., and M. O. Karlsson. 1999. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 58:51-64.
19. Kafetzis, D. A., D. C. Brater, A. N. Kapiki, C. V. Papas, H. Dellagrammaticas, and C. J. Papadatos. 1982. Treatment of severe neonatal infections with cefotaxime. Efficacy and pharmacokinetics. J. Pediatr. 100:483-489.
20. Kearns, G. L., R. F. Jacobs, B. R. Thomas, T. L. Darville, and J. M. Trang. 1989. Cefotaxime and desacetylcefotaxime pharmacokinetics in very low birth weight neonates. J. Pediatr. 114:461-467.
21. Lindbom, L., P. Pihlgren, and E. N. Jonsson. 2005. PsN-Toolkit - a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput. Methods Programs Biomed. 79:241-257.
22. Mandema, J. W., D. Verotta, and L. B. Sheiner. 1992. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J. Pharmacokinet. Biopharm. 20:511-528.
23. McCracken, G. H., Jr., N. E. Threlkeld, and M. L. Thomas. 1982. Pharmacokinetics of cefotaxime in newborn infants. Antimicrob. Agents Chemother. 21:683-684.
24. Mueller, M., A. de la Pena, and H. Derendorf. 2004. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob. Agents Chemother. 48:369-377.
25. Mulla, H., P. McCormack, G. Lawson, R. K. Firmin, and D. R. Upton. 2003. Pharmacokinetics of midazolam in neonates undergoing extracorporeal membrane oxygenation. Anesthesiology 99:275-282. (Pubitemid 36909552)
26. Mulla, H., F. Nabi, S. Nichani, G. Lawson, R. K. Firmin, and D. R. Upton. 2003. Population pharmacokinetics of theophylline during paediatric extracorporeal membrane oxygenation. Br. J. Clin. Pharmacol. 55:23-31.
27. Odio, C. M. 1995. Cefotaxime for treatment of neonatal sepsis and meningitis. Diagn. Microbiol. Infect. Dis. 22:111-117.
28. Paap, C. M., M. C. Nahata, M. A. Mentser, J. D. Mahan, S. K. Puri, and J. W. Hubbard. 1991. Pharmacokinetics of cefotaxime and its active metabolite in children with renal dysfunction. Antimicrob. Agents Chemother. 35:1879-1883.
29. Patel, K. B., D. P. Nicolau, C. H. Nightingale, and R. Quintiliani. 1995. Pharmacokinetics of cefotaxime in healthy volunteers and patients. Diagn. Microbiol. Infect. Dis. 22:49-55.
30. Savic, R. M., and M. O. Karlsson. 2007. Shrinkage in empirical Bayes estimates for diagnostics and estimation: problems and solutions. Population Approach Group Europe, Copenhagen, Denmark.
31. Trang, J. M., R. F. Jacobs, G. L. Kearns, A. L. Brown, T. G. Wells, F. L. Underwood, and R. B. Kluza. 1985. Cefotaxime and desacetylcefotaxime pharmacokinetics in infants and children with meningitis. Antimicrob. Agents Chemother. 28:791-795.
32. Wise, R., and N. Wright. 1985. The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction. Infection 13(Suppl. 1):S145-S150.
33. Wishart, D. S., C. Knox, A. C. Guo, D. Cheng, S. Shrivastava, D. Tzur, B. Gautam, and M. Hassanali. 2008. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 36:D901-D906.